Arkolith/Insider Trading/AVTX/Form 4

Doyle Mittie

Chief Medical OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed May 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$2.2M
Net Open-Market Flow
-$2.2M
Transactions
14
10 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 6, 2026Sell(S)45K$21.20$953K33K
May 6, 2026Sell(S)19K$22.41$426K14K
May 6, 2026Sell(S)10K$22.88$230K4K
May 6, 2026Option exercise(M)78K$12.65$985K82K
May 6, 2026Option exercise(M)29K$8.04$230K110K
May 6, 2026Sell(S)28K$18.03$496K83K
May 6, 2026Sell(S)5K$19.65$98K78K
May 5, 2026Option exercise(M)1K$12.65$13K5K
May 5, 2026Option exercise(M)679$8.04$5K5K
May 5, 2026Sell(S)2K$16.00$27K4K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 6, 2026Option exercise(M)78K—$0132K
May 6, 2026Option exercise(M)29K—$0119K
May 5, 2026Option exercise(M)1K—$0210K
May 5, 2026Option exercise(M)679—$0148K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001918845-26-000010) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML